• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » SEC levels FCPA charges against Stryker

SEC levels FCPA charges against Stryker

October 24, 2013 By Brad Perriello

SEC levels FCPA charges against Stryker

Stryker (NYSE:SYK) will pay $13.2 million to settle charges by the U.S. Securities & Exchange Commission that it broke the Foreign Corrupt Practices Act in 5 countries, the SEC said today.

Kalamazoo, Mich.-based Stryker’s subsidiaries in Argentina, Greece, Mexico, Poland, and Romania "made illicit payments totaling approximately $2.2 million that were incorrectly described as legitimate expenses in the company’s books and records," according to the SEC, resulting in $7.5 million in illicit profits.

"Descriptions varied from a charitable donation to consulting and service contracts, travel expenses, and commissions," according to the securities watchdog. Stryker admitted no wrongdoing in the settlement but promised "to cease and desist from committing or causing any violations" of the FCPA.

"Stryker’s misconduct involved 100s of improper payments over a number of years during which the company’s internal controls were fatally flawed," New York regional director Andrew Calamari said in prepared remarks. "Companies that allow corruption to occur by failing to implement robust compliance programs will not be allowed to profit from their misconduct."

The violations date back to 2003, the SEC said, and involved the use of 3rd parties to make payments to win or keep contracts. In 1 instance cited by the agency, Stryker’s Mexican subsidiary in January 2006 "directed a law firm to pay approximately $46,000 to a Mexican government employee in order to secure the winning bid on a contract."

"The result was $1.1 million in profits for Stryker. The subsidiary reimbursed the Mexico-based law firm for the bribe and booked the payment as a legitimate legal expense. However, no legal services were actually provided and the law firm simply acted as a funnel to pay the bribe," according to the SEC.

In another case a nearly $200,000 bribe to a Greek university for a lab run by a public hospital doctor prompted the doc to steer business Stryker’s way, the SEC said.

The SEC also found that Stryker used payments for travel and other expenses as bribes, citing a case in Poland.

Stryker will disgorge more than $7.5 million in profits plus $2.3 million in interest and a penalty of $3.5 million, according to the SEC.

Filed Under: Legal News, News Well Tagged With: Foreign Corrupt Practices Act, Securities & Exchange Commission (SEC), Stryker

More recent news

  • Siemens Healthineers completes $44M R&D, manufacturing site expansion
  • Next-gen Apple Watch Ultra 4 includes new health features
  • Johnson & Johnson wins CE mark for new reusable contact lens and other extra medtech news
  • Zimmer Biomet plans to cut 580 jobs in Switzerland
  • Verily Health secures investment from Nvidia to advance healthcare AI platforms

Primary Sidebar

Cart

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy